BenevolentAI Investor Conference Presentation Deck
BEN-8744 results and progress to date
Target
validation
2019
2020
2021
Novel, potent advanced lead molecule developed within 2 years
TARGET IDENTIFICATION
Novel target for UC
Discovered using Benevolent
TargetID tools
PDE10 has zero linkage to UC in
all available biomedical literature
Experimentally validated in
ex-vivo UC colon samples from
patients refractory to SoC treatment
Candidate nominated
CHEMISTRY
Rapid and efficient lead
optimisation
Preclinical development
ā Molecular Design tools enabled
rapid and efficient lead optimisation
ā Candidate nominated in Sep '21
Novel, potent, selective, peripherally
restricted PDE10. Inhibitor, with low
dose prediction
2022
Delivered drug candidate within
2 years from programme initiation
CTA Filed
2023
Phase I
clinical study
CLINICAL DEVELOPMENT
Developing responder and
progression endotypes
We will develop responder and
progression endotypes, adding
molecular descriptors
These will inform our trial design,
patient selection and further target
identification in UC
Augmenting a further loop of
iteration on an enriched graph
Benevolent 23View entire presentation